September 10th 2025, 2:59pm
The FDA has granted fast track designation to the cancer vaccine GLSI-100 for patients with HLA-A*02-positive and HER2-positive breast cancer.
September 10th 2025, 1:00pm
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
September 9th 2025, 9:17pm
The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
September 9th 2025, 7:00pm
For patients with relapsed/refractory mantle cell lymphoma Lunsumio plus Polivy was associated with durable responses.
September 9th 2025, 4:55pm
What does standing up to cancer mean to me? It means showing up for my life, even knowing that cancer is not a distant possibility but a biological reality.
September 9th 2025, 4:00pm
Patients with advanced, pretreated ROS1-positive NSCLC treated with zidesamtinib saw an objective response rate of 44%.
September 9th 2025, 3:11pm
For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.
September 9th 2025, 1:00pm
CURE spoke with the patient advocate and author of “Between Two Kingdoms” and “The Book of Alchemy.”
September 8th 2025, 9:00pm
The symbolism of seasons helped me to put some challenges of my cancer journey into perspective.
September 8th 2025, 8:00pm
CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.
Top Breast Cancer Stories from October 2025
New Book Spotlights Cancer in Early Adulthood
Top Gastrointestinal Cancer News: October 2025
Hairy Cell Leukemia Experts Impart Advice on Care and Support